ELAN has updated its full-year guidance to allow for a forecast of adjusted earnings before interest, tax, depreciation and amortisation (EBITDA) of $75 million (€50m), after it reported a switch from net loss to net profit for its third quarter.
Thu, 22 Oct, 2009
ELAN Drug Technologies (EDT) — the drug delivery arm of Irish pharmaceutical firm, Elan — stands to make nearly $8 million (€5.7m), before additional payments, from its manufacture of a new multiple sclerosis (MS) treatment for US pharma firms, Acorda Therapeutics and Biogen.
Thu, 02 Jul, 2009
EUROPEAN private equity house Cinven has reportedly ended any interest it had in acquiring Irish pharmaceutical company Elan’s drug research arm, Elan Drug Technology (EDT), which is currently being hawked around the market for potential buyers.
Fri, 22 Aug, 2008